Akcea IPO stumbles and falls well below the range, but still raises $175M
Investors weren’t willing to pay what Akcea Therapeutics $AKCA wanted for their IPO shares, but by adding to the load of stock on offer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
